European Union - English - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - narcolepsy - other nervous system drugs - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1).

Egypt - English - EDA (Egyptian Drug Authority)

wakid pharmaceutical industries (waki pharma) - doxycycline hyclate 554.6 mg (eq.to doxycycline base 500 mg)/1gm - water soluble powder

Israel - English - Ministry of Health

truemed ltd, israel - pitolisant as hydrochloride - film coated tablets - pitolisant as hydrochloride 17.8 mg - pitolisant - wakix is indicated• in adults for the treatment of narcolepsy with or without cataplexy. • to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa) whose eds has not been satisfactorily treated by, or who have not tolerated, osa primary therapy, such as continuous positive airway pressure (cpap).

Israel - English - Ministry of Health

truemed ltd, israel - pitolisant as hydrochloride - film coated tablets - pitolisant as hydrochloride 4.45 mg - pitolisant - wakix is indicated• in adults for the treatment of narcolepsy with or without cataplexy. • to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa) whose eds has not been satisfactorily treated by, or who have not tolerated, osa primary therapy, such as continuous positive airway pressure (cpap).

Egypt - English - EDA (Egyptian Drug Authority)

waki pharma -egypt - ivermectin 1gm /100ml - injectable solution

Egypt - English - EDA (Egyptian Drug Authority)

waki - pharma - gentamycin sulphate 12.6 gm (eq. to gentamycin base 10 gm) /100ml - injectable solution

Egypt - English - EDA (Egyptian Drug Authority)

waki - pharma - levamisole hcl 7.5 gm ( eq. to levamisole base 6.75 gm) /100ml - injectable solution

Egypt - English - EDA (Egyptian Drug Authority)

waki pharma - oxytetracycline dihydrate 21.6 g ( eq. to oxytetracycline base 20 g ) / 100 ml - injectable solution

United States - English - NLM (National Library of Medicine)

harmony biosciences, llc - pitolisant hydrochloride (unii: yv33ch63hi) (pitolisant - unii:4bc83l4piy) - wakix is indicated for the treatment of excessive daytime sleepiness (eds) or cataplexy in adult patients with narcolepsy. wakix is contraindicated in patients with: - known hypersensitivity to pitolisant or any component of the formulation. anaphylaxis has been reported in patients treated with wakix [see adverse reactions (6.2)] . - severe hepatic impairment. wakix is extensively metabolized by the liver and there is a significant increase in wakix exposure in patients with moderate hepatic impairment [see use in specific populations (8.6)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to wakix during pregnancy. patients should be encouraged to enroll in the wakix pregnancy registry if they become pregnant. to enroll or obtain information from the registry, patients can call 1-800-833-7460. risk summary available case reports from clinical trials and postmarketing reports with wakix use in pregnant women have not determined a d

Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products